Cue Biopharma Inc (NAS:CUE)
$ 1.56 -0.09 (-5.45%) Market Cap: 75.88 Mil Enterprise Value: 51.74 Mil PE Ratio: 0 PB Ratio: 2.52 GF Score: 52/100

Cue Biopharma Inc To Host Business Update And Ongoing CUE-101 Clinical Trials Call Transcript

Jan 26, 2022 / 09:30PM GMT
Release Date Price: $10.6 (+8.27%)
Operator

Greetings, and welcome to the Cue Biopharma update call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to Dan Passeri, Cue Biopharma's Chief Executive Officer. Thank you. You may begin.

Daniel R. Passeri
Cue Biopharma, Inc. - CEO & Director

Okay. Thank you, and good afternoon, everyone. We appreciate your time and interest in our update call regarding recent data and observations from our ongoing clinical trials of CUE-101, which is our first drug candidate representative of the IL-2-based CUE-100 series.

Joining me on today's call is Dr. Anish Suri, our President and Chief Scientific Officer; Dr. Ken Pienta, our acting Chief Medical Officer; and Dr. Matteo Levisetti, our Senior Vice President of Clinical Development.

So this conference is being recorded and will be available on our website for the next 30 days. As a reminder, and as shown here on Slide #2, this presentation and overview may contain some forward-looking statements. And any forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot